A Phase 3 interventional study of Insulin Glargine (LANTUS) and Insulin Glulisine (Apidra) in AMI, sponsored by Sanofi. Terminated at 5 sites in 5 countries. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-02-11.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary objective:
To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and insulin glargine, i.e. Intensive Insulin Therapy (IIT), results in reducing infarct size at day 60 versus (vs) Standard Glycemic Care (SGC).
Secondary objectives:
To demonstrate that tight glycemic control using insulin glulisine and insulin glargine reduces markers of inflammation and improves Left Ventricular (LV) function and Cardio-Vascular (CV) outcomes from baseline values, in hyperglycemic subjects with STEMI undergoing Percutaneous Coronary Intervention (PCI).
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
to MRI: a)Intracranial aneurysm clips (Unless the investigator is certain that it is made of non-ferromagnetic material such as titanium)b)Intra-orbital metal fragments c)Any electrically, magnetically or mechanically activated implants (including cardiac pacemakers, biostimulators, neurostimulators, cochlear implants, and hearing aids) d)Warning about Gadolinium-based contrast agents (GBCAs) Exposure to GBCAs increases the risk for nephrogenic systemic fibrosis (NSF). Therefore the following subjects should be excluded from the trial based on a history and/or laboratory tests:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In IIT arm, subjects received intravenous (IV) insulin glulisine and subcutaneous (sc) insulin glargine to maintain a Blood Glucose (BG) concentration between 90-130 mg/dL.
Drug: Insulin Glargine (LANTUS) · Drug: Insulin Glulisine (Apidra)
In SGC arm subjects assigned to "standard of care" received subcutaneous regular insulin per sliding scale.
Drug: Standard Therapy
Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight. Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL.
Standard insulin therapy titrated to blood sugar control
Also known as: multiple insulins per hospital protocol
Infarct Size Absolute Change From Baseline at Day 60
Infarct size is measured by cardiac Magnetic Resonance Imaging (MRI) as the percentage of Left Ventricular (LV) mass.
Time frame: From baseline at Day 60
Left Ventricular (LV) Function Evaluated by Cardiac Magnetic Resonance Imaging (MRI)
Due to study early termination and the limited number of randomized subjects, descriptive statistics for the Day 3 Ejection Fraction were selected for presentation instead of for Day 60 as initially planned.
Time frame: At Day 3
Occurrence of the Major Adverse Cardiovascular Events (MACE)
MACE: Cardiac death, New onset or worsening congestive heart failure (\>24 h post-admission) event evaluating using New York Heart Association (NYHA) Class II or greater Non-fatal Myocardial Infarction, Severe arrhythmia, Stroke/TIA (Transient Ischemic Attack), Cardiogenic shock, Catheterization/revascularization, Unstable angina leading to hospitalisation
Time frame: At Day 60
Biomarkers of Inflammation Measurement: CRP (C-Reactive Protein)
Time frame: At Day 60
Multicenter study: 60 out of the 90 centers planned were initiated. Only 17 centers randomized patients (i.e. 7 sites in the United States, 5 sites in Argentina, 3 sites in Brazil and 2 sites in Mexico).
| Milestone | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) |
|---|---|---|
| Started | 18 | 15 |
| Completed | 13 | 12 |
| Not completed | 5 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death or mace | 0 | 1 |
| Withdrew: Not treated | 2 | 2 |
| Withdrew: Not meeting the selection criteria | 2 | 0 |
Infarct size is measured by cardiac Magnetic Resonance Imaging (MRI) as the percentage of Left Ventricular (LV) mass.
| percentage of LV mass change | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) |
|---|---|---|
| Infarct Size Absolute Change From Baseline at Day 60 | -7.84 ± 9.19 | -15.72 ± 22.41 |
Due to study early termination and the limited number of randomized subjects, descriptive statistics for the Day 3 Ejection Fraction were selected for presentation instead of for Day 60 as initially planned.
| percentage of Ejection Fraction | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) |
|---|---|---|
| Left Ventricular (LV) Function Evaluated by Cardiac Magnetic Resonance Imaging (MRI) | 43.08 ± 11.34 | 43.43 ± 6.87 |
MACE: Cardiac death, New onset or worsening congestive heart failure (\>24 h post-admission) event evaluating using New York Heart Association (NYHA) Class II or greater Non-fatal Myocardial Infarction, Severe arrhythmia, Stroke/TIA (Transient Ischemic Attack), Cardiogenic shock, Catheterization/revascularization, Unstable angina leading to hospitalisation
| events | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) |
|---|---|---|
| Severe arrhythmia | 7 | 2 |
| Shock | 0 | 1 |
| Revascularization | 1 | 0 |
| New onset or worsening of congestive heart failure | 1 | 0 |
| Myocardial Infarction (MI) | 1 | 0 |
| Death | 1 | 1 |
| mg/L | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) |
|---|---|---|
| Biomarkers of Inflammation Measurement: CRP (C-Reactive Protein) | 2.52 ± 2.10 | 2.96 ± 4.07 |
Collected over Adverse events are collected from the first to the last drug intake + 1 week after the administration of the last intake i.e. end of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intensive Insulin Therapy (IIT) | — | 6/16 (37.5%) | 10/16 (62.5%) |
| Standard Glycemic Care (SGC) | — | 3/13 (23.1%) | 6/13 (46.2%) |
| Event | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) |
|---|---|---|
| Ventricular TachycardiaCardiac disorders | 0/16 | 2/13 |
| BradycardiaCardiac disorders | 2/16 | 0/13 |
| HypotensionVascular disorders | 2/16 | 0/13 |
| Cardiac Failure CongestiveCardiac disorders | 0/16 | 1/13 |
| Cardiogenic ShockCardiac disorders | 1/16 | 1/13 |
| Pericardial EffusionCardiac disorders | 1/16 | 0/13 |
| PericarditisCardiac disorders | 1/16 | 0/13 |
| Sinus TachycardiaCardiac disorders | 1/16 | 0/13 |
| BronchopneumoniaInfections and infestations | 1/16 | 0/13 |
| PneumoniaInfections and infestations | 1/16 | 0/13 |
| Event | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) |
|---|---|---|
| HypotensionVascular disorders | 4/16 | 0/13 |
| Ventricular ExtrasystolesCardiac disorders | 0/16 | 2/13 |
| NauseaGastrointestinal disorders | 1/16 | 2/13 |
| VomitingGastrointestinal disorders | 1/16 | 2/13 |
| Myocardial InfarctionCardiac disorders | 2/16 | 0/13 |
| ConstipationGastrointestinal disorders | 2/16 | 0/13 |
| Vessel Puncture Site HaematomaGeneral disorders | 2/16 | 1/13 |
| HypokalaemiaMetabolism and nutrition disorders | 2/16 | 0/13 |
| Back PainMusculoskeletal and connective tissue disorders | 2/16 | 1/13 |
| HeadacheNervous system disorders | 2/16 | 1/13 |
| Age Continuous(years) | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) | Total |
|---|---|---|---|
| Mean | 61.11 ± 10.95 | 62.80 ± 11.12 | 61.88 ± 10.89 |
| Sex: Female, Male(Participants) | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) | Total |
|---|---|---|---|
| Female | 6 | 2 | 8 |
| Male | 12 | 13 | 25 |
| Body Mass Index (BMI)(Kg/m^2) | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) | Total |
|---|---|---|---|
| Mean | 26.95 ± 3.34 | 28.49 ± 3.92 | 27.65 ± 3.64 |
| Diabetes diagnosis at study entry(participants) | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) | Total |
|---|---|---|---|
| Yes | 6 | 7 | 13 |
| No | 12 | 8 | 20 |
| Duration of Diabetes at study entry(Years) | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) | Total |
|---|---|---|---|
| Mean | 9.50 ± 9.20 | 7.50 ± 6.80 | 8.50 ± 7.79 |
| Mean time to Percutaneous Coronary Intervention (PCI)(minutes) | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) | Total |
|---|---|---|---|
| Mean | 110.00 ± 112.69 | 101.54 ± 51.47 | 106.07 ± 88.21 |
| Myocardial Infarction (MI) duration greater than 3 hours(participants) | Intensive Insulin Therapy (IIT) | Standard Glycemic Care (SGC) | Total |
|---|---|---|---|
| No | 13 | 9 | 22 |
| Yes | 5 | 6 | 11 |
The record gives a start of Apr 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Glargine · Insulin glulisine